Haleon plc (LON: HLN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 34.34B |
| Revenue (ttm) | 11.26B |
| Net Income (ttm) | 1.09B |
| Shares Out | 9.05B |
| EPS (ttm) | 0.12 |
| PE Ratio | 32.18 |
| Forward PE | 20.43 |
| Dividend | 0.06 (1.63%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 19,936,481 |
| Open | 379.30 |
| Previous Close | 379.30 |
| Day's Range | 378.70 - 383.50 |
| 52-Week Range | 308.37 - 400.65 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 5, 2025 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops,... [Read more]
Financial Performance
In 2023, Haleon's revenue was 11.30 billion, an increase of 4.09% compared to the previous year's 10.86 billion. Earnings were 1.05 billion, a decrease of -1.04%.
Financial StatementsNews
Tombras Acquires New York Agency The Burns Group
Global independent agency Tombras has acquired The Burns Group, an independent advertising agency based in New York. The acquisition further bolsters Tombras' capabilities with top CPG clients, includ...
Pfizer sells further shares in Sensodyne maker Haleon for £2.4bn
Haleon was formed in 2019 by the merger of the consumer healthcare businesses of GSK and US rival Pfizer, but was spun out and floated in 2022.
Pfizer cuts Haleon stake in $3.3B share sale
Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual divestment strategy. Read more here.
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer Inc. (NYSE: PFE) has divested a $3.3 billion stake in Haleon (NYSE: HLN), reducing its holding in the British consumer healthcare company. What Happened : The transaction occurred on Monday, ...
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Dr Reddy's completes acquisition of UK co Haleon's non-US nicotine replacement therapy biz
Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal includes b...
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
20 'Every Day Stocks' I'd Struggle To Live Without
In this article, I go through a typical day and note 20 stocks whose revenue I contribute to, and would find it difficult not to. One motivation was to see how much of my budget at attention go into M...
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves an...
Top 2 Risk Off Stocks That May Implode In August
As of Aug 9, 2024, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon PLC (HLN) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue Growth and ...
Haleon PLC (HLN) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Moves
Half Year 2024 Haleon PLC Earnings Call Transcript
Half Year 2024 Haleon PLC Earnings Call Transcript
Haleon plc 2024 Q2 - Results - Earnings Call Presentation
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:NYSE:HLN) Q2 2024 Earnings Call August 1, 2024 4:00 AM ETCompany ParticipantsSonya Ghobrial - Investor RelationsBrian McNamara - Chief...
Haleon plc reports 1H results
Haleon sees high single-digit growth for annual organic operating profit
Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its ...
What next for Haleon shares? Analysts say consumer spin-off is undervalued
Berenberg also argues that the shares are trading at a tempting 17 per cent discount to other personal care products groups.
Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's Laboratories (NYSE: RDY) has announced a definitive agreement with Haleon plc (NYSE: HLN) to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therap...
Dr Reddy’s to buy UK co’s nicotine gum biz for ₹5k cr
Dr Reddy’s Laboratories makes its biggest acquisition by buying British consumer healthcare giant Haleon's nicotine replacement therapy portfolio, excluding the US business, for approximately ₹5,275 c...
Dr Reddy's to acquire British consumer healthcare co Haleon's entire non-US nicotine therapy business
Dr Reddy's Laboratories is set to acquire Haleon Plc's NRT business, including Nicotinell, for GBP 500 million. The deal encompasses various NRT formats and potential contingent payments. This acquisi...
Haleon sells nicotine replacement therapy business outside of US for £500m
The healthcare giant said it was selling its nicotine replacement therapy business to a division of Indian drugmaker Dr Reddy’s Laboratories.